Carl F. Ware, Ph.D., director of the Inflammatory Diseases Center at Sanford Burhnam Prebys, has received the 2021 International Cytokine & Interferon Society Honorary Lifetime Membership Award.
Gut issues are common with endurance exercise, ranging from mild discomfort to severe debilitating symptoms warranting reduced exercise workload or even cessation from activity. Considering the recent exponential growth of nighttime endurance and ultra-endurance events, athletes anecdotally report having more…
Article title: Interleukin-28A induces epithelial barrier dysfunction in [Crohn’s disease] patient-derived intestinal organoids Authors: Pan Xu, Heike Becker, Montserrat Elizalde, Marieke Pierik, Ad A.M. Masclee, Daisy M.A.E. Jonkers From the authors: “These results identified IL-28A as a novel regulator of…
A new study from Washington University School of Medicine in St. Louis has uncovered a previously unknown role for exosomes in inflammatory respiratory diseases. The study has implications for finding new therapies. Exosomes are tiny compartments released from cells that carry different types of cargo, including inflammatory chemicals called cytokines that can drive lung disease.
Researchers have created an experimental device that, instead of inhibiting inflammatory proteins in COVID-19 patients, changes the phenotype of circulating white blood cells, helping wean two patients off ECMO.
Researchers at Canada’s McMaster University and SQI Diagnostics have created a surface that repels every other element of human blood except a critical indicator of infection, opening a timely window for understanding the progress of COVID-19 in individual patients.
In addition to its predictive value, the discovery could lead to new treatments to prevent deadly cytokine storms. It also may help explain why diabetes contributes to worse outcomes in patients with COVID-19.
A drug is being studied for its effectiveness in treating a type of severe immune overreaction seen in patients with COVID-19-induced pneumonia by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.